Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

Fineline Cube Jul 6, 2026
Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Fineline Cube Jul 6, 2026
Company Deals

Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services

Fineline Cube Jun 15, 2026

Ningbo Sanxing Medical Electric Co., Ltd. announced it has filed its prospectus for listing on...

Company Drug

Gritpharma Secures NMPA Approval for Doxylamine as China’s First Novel Short-Term Insomnia Treatment

Fineline Cube Jun 15, 2026

Nanjing Gritpharma Co., Ltd. announced it has received marketing approval from China’s National Medical Products...

Company Deals Hospital Medical Device

Baheal Pharma Partners with Jinan Junxin Hospital to Launch ZAP-X Precision Radiosurgery Center

Fineline Cube Jun 15, 2026

Baheal Pharma Group (SHE: 301015) announced a strategic partnership with Jinan Junxin Cancer Hospital to...

Company Deals

Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline

Fineline Cube Jun 15, 2026

Yantai Lannacheng Biotechnology Co., Ltd. announced it has filed its prospectus for listing on the...

Company Legal / IP

Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court

Fineline Cube Jun 15, 2026

Harbour BioMed (HKG: 2142) announced that a jury in the U.S. District Court for the...

Company Drug

Sichuan Biokin’s Iza-Bren Becomes World’s First EGFR×HER3 Bispecific ADC with NDA Accepted by China’s NMPA

Fineline Cube Jun 15, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for...

Company Deals

SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health

Fineline Cube Jun 15, 2026

SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with...

Company Deals

Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy

Fineline Cube Jun 15, 2026

Simcere Pharmaceutical Group (HKG: 2096) announced a collaborative research agreement with Stanford University School of...

Company Drug

Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency

Fineline Cube Jun 15, 2026

Novo Nordisk (NYSE: NVO) announced that its long-acting growth hormone injection Sogroya (somapacitan) will be...

Company Deals

Medtronic Completes $550 Million Acquisition of Scientia Vascular to Strengthen Neurovascular Portfolio

Fineline Cube Jun 15, 2026

Medtronic (NYSE: MDT) announced on June 12, 2026 the completion of its acquisition of Scientia...

Company Drug

Sanofi’s Tzield Receives FDA Approval to Preserve Insulin Production in Recently Diagnosed Type 1 Diabetes

Fineline Cube Jun 15, 2026

Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated...

Company Medical Device

Roche’s VENTANA PTEN Assay Receives FDA Approval as First Companion Diagnostic for AstraZeneca’s Truqap in Prostate Cancer

Fineline Cube Jun 15, 2026

Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced that the VENTANA PTEN (SP218) RxDx Assay...

Company Drug

Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer

Fineline Cube Jun 15, 2026

Jazz Pharmaceuticals (NASDAQ: JAZZ) announced on June 12, 2026 that the Phase 3 LAGOON trial,...

Company Drug

AstraZeneca’s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer

Fineline Cube Jun 15, 2026

AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved...

Company Deals

Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO

Fineline Cube Jun 15, 2026

Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong...

Company Drug

Merck Secures FDA Approval for Keytruda-Welireg Combination as Adjuvant Therapy in High-Risk Kidney Cancer

Fineline Cube Jun 15, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that the U.S. Food and Drug Administration...

Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026

China’s National Healthcare Security Administration (NHSA) announced that the application period for the 2026 adjustment...

Company Drug

Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors

Fineline Cube Jun 15, 2026

Simcere Pharmaceutical Group (HKG: 2096) announced that SIM0689, a novel bispecific antibody (BsAb) targeting both...

Company Drug

Mabwell Bioscience Secures FDA Approval for 6MW5311 Bispecific Antibody Trial in Hematologic Malignancies

Fineline Cube Jun 15, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that the U.S. Food and Drug Administration...

Company Deals

Qingfeng Pharmaceutical Group Partners with TASCO PHARMA to Commercialize Anti-Tumor and CNS Medicines in Vietnam

Fineline Cube Jun 15, 2026

Qingfeng Pharmaceutical Group announced a strategic commercialization cooperation agreement with Vietnam’s TASCO PHARMA for the...

Posts pagination

1 … 7 8 9 … 690

Recent updates

  • Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic
  • Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment
  • China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways
  • Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment
  • Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Others

China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways

Company Drug

Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.